CN102428084B - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- CN102428084B CN102428084B CN201080021866.0A CN201080021866A CN102428084B CN 102428084 B CN102428084 B CN 102428084B CN 201080021866 A CN201080021866 A CN 201080021866A CN 102428084 B CN102428084 B CN 102428084B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- optionally
- group
- replaces
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C=C1C(*C2CCOCC2)C1 Chemical compound C=C1C(*C2CCOCC2)C1 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- SAVORVAQVQNIKX-UHFFFAOYSA-N C(CC1)CN1c1n[n](C(c2ccccc2)(c2ccccc2)c2ccccc2)c2ccnc(OC3CCCCC3)c12 Chemical compound C(CC1)CN1c1n[n](C(c2ccccc2)(c2ccccc2)c2ccccc2)c2ccnc(OC3CCCCC3)c12 SAVORVAQVQNIKX-UHFFFAOYSA-N 0.000 description 1
- OVRKATYHWPCGPZ-UHFFFAOYSA-N CC1CCOCC1 Chemical compound CC1CCOCC1 OVRKATYHWPCGPZ-UHFFFAOYSA-N 0.000 description 1
- SBGKQFAWXQVYRR-UHFFFAOYSA-N COC(CCc1n[nH]c2ccnc(NC3CC=CCC3)c12)=O Chemical compound COC(CCc1n[nH]c2ccnc(NC3CC=CCC3)c12)=O SBGKQFAWXQVYRR-UHFFFAOYSA-N 0.000 description 1
- YDMAYVQZRDGDLJ-SCOAYWHSSA-N COc1c(c(/C=C/C(N(CCC2)C[C@H]2c2ccccc2)=O)n[nH]2)c2ccn1 Chemical compound COc1c(c(/C=C/C(N(CCC2)C[C@H]2c2ccccc2)=O)n[nH]2)c2ccn1 YDMAYVQZRDGDLJ-SCOAYWHSSA-N 0.000 description 1
- ANSYNDLUWKDTTQ-RAXLEYEMSA-N Cc1ccnc(Cl)c1/C(/C1CC1)=N\C Chemical compound Cc1ccnc(Cl)c1/C(/C1CC1)=N\C ANSYNDLUWKDTTQ-RAXLEYEMSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Nc1ccccc1 Chemical compound Nc1ccccc1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65611—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. penicillins and analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0904746A GB0904746D0 (en) | 2009-03-19 | 2009-03-19 | Compounds |
| GB0904746.5 | 2009-03-19 | ||
| US16202409P | 2009-03-20 | 2009-03-20 | |
| US61/162,024 | 2009-03-20 | ||
| GB0912238A GB0912238D0 (en) | 2009-07-14 | 2009-07-14 | Compounds |
| GB0912238.3 | 2009-07-14 | ||
| GBGB1001418.1A GB201001418D0 (en) | 2010-01-28 | 2010-01-28 | Compounds |
| GB1001418.1 | 2010-01-28 | ||
| PCT/GB2010/000498 WO2010106333A1 (en) | 2009-03-19 | 2010-03-19 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102428084A CN102428084A (zh) | 2012-04-25 |
| CN102428084B true CN102428084B (zh) | 2016-05-18 |
Family
ID=42226628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080021866.0A Active CN102428084B (zh) | 2009-03-19 | 2010-03-19 | 化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20100317646A1 (https=) |
| EP (1) | EP2408772B1 (https=) |
| JP (1) | JP5732036B2 (https=) |
| KR (1) | KR101700229B1 (https=) |
| CN (1) | CN102428084B (https=) |
| AU (1) | AU2010224693B2 (https=) |
| CA (1) | CA2754605C (https=) |
| CL (1) | CL2011002267A1 (https=) |
| IL (1) | IL215147A0 (https=) |
| MX (1) | MX2011009807A (https=) |
| PE (1) | PE20120506A1 (https=) |
| RU (1) | RU2011142182A (https=) |
| WO (1) | WO2010106333A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2451676C2 (ru) * | 2006-08-16 | 2012-05-27 | Ф.Хоффманн-Ля Рош Аг | Ненуклеозидные ингибиторы обратной транскриптазы |
| GB201008134D0 (en) * | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| US9233977B2 (en) * | 2010-10-29 | 2016-01-12 | Merck Sharp & Dohme Corp. | Leucine-rich repeat kinase enzyme activity |
| US20130338106A1 (en) * | 2011-02-28 | 2013-12-19 | John A. McCauley | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US8791112B2 (en) | 2011-03-30 | 2014-07-29 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
| AU2012244549B2 (en) * | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| RU2637936C2 (ru) * | 2011-05-23 | 2017-12-08 | Элан Фармасьютикалз, Инк. | Ингибиторы активности киназы lrrk2 |
| CN102558174B (zh) * | 2011-08-23 | 2014-03-19 | 天津市斯芬克司药物研发有限公司 | 一种全新吡唑并[4,3-c]吡啶化合物的发明及其合成方法 |
| HUE029728T2 (en) * | 2011-09-30 | 2017-03-28 | Ipsen Pharma Sas | Macrocyclic LRRK2 kinase inhibitors |
| GB201204985D0 (en) | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| WO2013182612A1 (en) | 2012-06-07 | 2013-12-12 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| EP2867236B1 (en) * | 2012-06-29 | 2017-06-14 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| WO2014026330A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014060113A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
| ES2661585T3 (es) * | 2012-10-31 | 2018-04-02 | Raqualia Pharma Inc | Derivados de pirazolopiridina como bloqueadores de TTX-S |
| AU2013343105B2 (en) * | 2012-11-08 | 2016-04-14 | Pfizer Inc. | Heteroaromatic compounds as dopamine D1 ligands |
| WO2014150981A1 (en) * | 2013-03-15 | 2014-09-25 | Elan Pharmaceuticals, Llc | Inhibitors of lrrk2 kinase activity |
| US9045477B2 (en) * | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201533043A (zh) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| TW201534597A (zh) | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
| US9718818B2 (en) * | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| EP3134405B1 (en) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
| KR20170002623A (ko) | 2014-05-14 | 2017-01-06 | 화이자 인코포레이티드 | 피라졸로피리딘 및 피라졸로피리미딘 |
| EP3190889B1 (en) | 2014-09-03 | 2021-11-17 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| US10918645B2 (en) | 2016-06-15 | 2021-02-16 | Lifearc | Substituted tricyclic heterocyclic compounds and use thereof |
| KR101923852B1 (ko) | 2017-02-24 | 2018-11-29 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| KR101990738B1 (ko) * | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| JP2023504623A (ja) * | 2019-12-04 | 2023-02-06 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ｈｉｆ－２アルファの阻害剤 |
| KR20230026479A (ko) | 2020-06-22 | 2023-02-24 | 에프. 호프만-라 로슈 아게 | 설폰 유도체 |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
| KR20240144325A (ko) * | 2022-02-25 | 2024-10-02 | 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 | 치환된 융합 고리 화합물 및 이의 약학적 조성물, 제조 방법과 용도 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017062A1 (en) * | 1993-01-28 | 1994-08-04 | Zeneca Limited | Substituted fused pyrazolo compounds and their use as herbicides |
| WO2006077319A1 (fr) * | 2005-01-19 | 2006-07-27 | Aventis Pharma S.A. | Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation |
| EP1772454A1 (en) * | 2004-07-23 | 2007-04-11 | Tanabe Seiyaku Co., Ltd. | Nitrogenous fused bicyclic compound |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835144A (en) * | 1972-06-16 | 1974-09-10 | Squibb & Sons Inc | Amino derivatives of (4,3-c pyrazolopyridine cabroxylic acids and esters |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US5478830A (en) * | 1992-05-29 | 1995-12-26 | The Du Pont Merck Pharmaceutical Company | Fused-ring heterocycles for the treatment of atherosclerosis |
| US7429609B2 (en) * | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| EP1545515A1 (en) * | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| US7348338B2 (en) * | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| WO2005016875A2 (en) * | 2003-08-06 | 2005-02-24 | Sugen, Inc. | Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors |
| WO2005121094A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Limited | Piperazine and piperidine derivatives as anti-hiv-agents |
| EP1989330A4 (en) * | 2006-01-31 | 2009-10-21 | Elan Pharm Inc | ALPHA-SYNUCLEINE KINASE |
| US20100273776A1 (en) * | 2006-03-29 | 2010-10-28 | FOLDRx PHARMACEUTICALS, INC | Inhibition of alpha-synuclein toxicity |
| NZ591115A (en) * | 2008-09-26 | 2012-10-26 | Boehringer Ingelheim Int | Azaindazole compounds as ccr1 receptor antagonists |
| GB201015949D0 (en) * | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
-
2010
- 2010-03-19 EP EP10711443.1A patent/EP2408772B1/en not_active Not-in-force
- 2010-03-19 RU RU2011142182/04A patent/RU2011142182A/ru unknown
- 2010-03-19 CA CA2754605A patent/CA2754605C/en not_active Expired - Fee Related
- 2010-03-19 JP JP2012500308A patent/JP5732036B2/ja not_active Expired - Fee Related
- 2010-03-19 AU AU2010224693A patent/AU2010224693B2/en not_active Ceased
- 2010-03-19 WO PCT/GB2010/000498 patent/WO2010106333A1/en not_active Ceased
- 2010-03-19 PE PE2011001662A patent/PE20120506A1/es not_active Application Discontinuation
- 2010-03-19 KR KR1020117024068A patent/KR101700229B1/ko not_active Expired - Fee Related
- 2010-03-19 MX MX2011009807A patent/MX2011009807A/es not_active Application Discontinuation
- 2010-03-19 CN CN201080021866.0A patent/CN102428084B/zh active Active
- 2010-03-19 US US12/727,754 patent/US20100317646A1/en not_active Abandoned
-
2011
- 2011-09-13 CL CL2011002267A patent/CL2011002267A1/es unknown
- 2011-09-14 IL IL215147A patent/IL215147A0/en unknown
-
2017
- 2017-04-03 US US15/478,141 patent/US20170320870A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017062A1 (en) * | 1993-01-28 | 1994-08-04 | Zeneca Limited | Substituted fused pyrazolo compounds and their use as herbicides |
| EP1772454A1 (en) * | 2004-07-23 | 2007-04-11 | Tanabe Seiyaku Co., Ltd. | Nitrogenous fused bicyclic compound |
| WO2006077319A1 (fr) * | 2005-01-19 | 2006-07-27 | Aventis Pharma S.A. | Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2754605C (en) | 2018-04-17 |
| CN102428084A (zh) | 2012-04-25 |
| PE20120506A1 (es) | 2012-05-14 |
| KR101700229B1 (ko) | 2017-01-26 |
| IL215147A0 (en) | 2011-12-29 |
| US20170320870A1 (en) | 2017-11-09 |
| RU2011142182A (ru) | 2013-04-27 |
| CA2754605A1 (en) | 2010-09-23 |
| JP5732036B2 (ja) | 2015-06-10 |
| EP2408772B1 (en) | 2015-07-01 |
| MX2011009807A (es) | 2011-09-29 |
| EP2408772A1 (en) | 2012-01-25 |
| KR20110128925A (ko) | 2011-11-30 |
| JP2012520861A (ja) | 2012-09-10 |
| AU2010224693A1 (en) | 2011-09-15 |
| WO2010106333A1 (en) | 2010-09-23 |
| CL2011002267A1 (es) | 2012-05-11 |
| AU2010224693B2 (en) | 2016-07-28 |
| US20100317646A1 (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102428084B (zh) | 化合物 | |
| KR101196498B1 (ko) | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘유도체 | |
| US8569281B2 (en) | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | |
| EP3190889B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| KR101088922B1 (ko) | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 | |
| JP2013529196A (ja) | キナーゼｌｒｒｋ２の阻害剤としてのピラゾロピリジン | |
| EP3068389B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| CN100376580C (zh) | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 | |
| CA2736304A1 (en) | Pyrazolopyrimidines and their use for the treatment of cns disorders | |
| CN101321756A (zh) | 用作细胞周期蛋白依赖性激酶抑制剂的新的吡唑并嘧啶化合物 | |
| CN102341400A (zh) | 用作激酶抑制剂的吡咯并嘧啶化合物 | |
| CN106795152B (zh) | 蛋白激酶抑制剂 | |
| CN108368114A (zh) | 作为mnk抑制剂的吡咯并嘧啶化合物 | |
| CN109071558B (zh) | 取代的三环杂环化合物及其用途 | |
| CN110114355A (zh) | 用于治疗癌症的噁唑衍生物 | |
| Meniconi | Heteroaryl derivatives as sepiapterin reductase inhibitors | |
| HK1260037B (zh) | 取代的三环杂环化合物及其用途 | |
| HK1260037A1 (en) | Substituted tricyclic herteocyclic compounds and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: London, England Patentee after: Life arc company Address before: London, England Patentee before: Medical Res Council Technology |